Premium
[ 123 I]FP‐CIT SPET imaging in drug‐induced Parkinsonism
Author(s) -
Tinazzi Michele,
Ottaviani Sarah,
Isaias Ioannis U.,
Pasquin Isabella,
Steinmayr Maria,
Vampini Claudio,
Pilleri Manuela,
Moretto Giuseppe,
Fiaschi Antonio,
Smania Nicola,
Giorgetti Piergiorgio,
Antonini Angelo
Publication year - 2008
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22098
Subject(s) - parkinsonism , nuclear medicine , medicine , central nervous system disease , disease
We assessed the status of dopamine nerve terminals in patients treated with dopamine receptor blocking agents (DRBAs) who had developed drug‐induced parkinsonism (DIP). We performed [ 123 I]FP‐CIT SPET in 32 consecutive patients who were on DRBAs for at least 6 months and developed extrapyramidal signs. The UPDRS‐III was used to assess clinical severity. Twenty‐six age‐ and sex‐matched healthy subjects served as control group. Putamen [ 123 I]FP‐CIT SPET binding was reduced in 14 and normal in the remaining 18 patients. There was no difference between the two groups for age, duration of DRBAs treatment, UPDRS III, tremor, rigidity, and bradykinesia subscores for upper and lower limbs. Conversely, symmetry of parkinsonian signs and presence bucco‐linguo‐masticatory dyskinesias were more frequent in individuals with normal tracer binding. Imaging of the dopamine transporter may help to identify subjects with DIP secondary to a loss of dopamine nerve terminals. © 2008 Movement Disorder Society